Sisram Medical在泰国加强能量源设备与注射类产品业务，以释放亚太区增长潜力

With advancing EBD rollout and steady injectables expansion, integrated treatment protocols deliver unique competitive edges for high-quality regional growth

随着EBD的逐步推广和注射剂业务的稳步扩张，一体化治疗方案为高质量区域增长提供了独特的竞争优势

HONG KONG

香港

,

，

June 22, 2026

2026年6月22日

/PRNewswire/ -- Sisram Medical Ltd (the '

/美通社/ -- Sisram Medical Ltd（“

Company

公司

' or '

' 或 '

Sisram

复锐医疗科技

', 1696.HK), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, has officially rolled out its Soprano Titanium across Thailand. Supported by its on-the-ground local team and well-established sales network, Sisram has successfully expanded its footprint across both EBD and injectable lines, solidifying Thailand as a core strategic hub and unlocking substantial growth opportunities throughout Southeast Asia..

复锐医疗科技（1696.HK）是一家提供能量源设备（EBD）、注射类及其他互补解决方案的全球健康集团，已在泰国正式推出其Soprano Titanium产品。凭借本地化团队的支持和成熟的销售网络，复锐医疗科技成功扩展了其在能量源设备和注射类产品线的市场覆盖，巩固了泰国作为核心战略枢纽的地位，并为整个东南亚地区释放出巨大的增长机遇。

Building on its direct local sales operations launched in 2025 and long-term partnerships with leading aesthetic clinics, the Soprano Titanium has secured strong market uptake and broad recognition among local partners. This launch marks a major milestone for the Company's dual-engine growth strategy in Thailand.

依托2025年启动的直接本地销售业务以及与领先医美诊所建立的长期合作伙伴关系，Soprano Titanium赢得了强劲的市场接纳度，并在本地合作伙伴中获得了广泛认可。此次发布标志着公司在泰国双引擎增长战略的重要里程碑。

A pipeline of additional EBD models is currently undergoing local regulatory registration and is scheduled for release in the second half of 2026, further diversifying the Company's regional product portfolio..

更多EBD模型的产品线目前正在接受当地监管注册，并计划于2026年下半年发布，进一步丰富公司区域产品组合。

Sisram's injectable business continues to deliver strong results in the market. Following a stellar performance in 2025, flagship product Profhilo has maintained robust momentum in Thailand's premium medical aesthetics sector throughout 2026. Widely adopted by top-tier clinics and seasoned practitioners, the product enjoys sustained end-consumer demand, bolstering Sisram's brand standing in the injectables segment and expanding industry collaboration locally..

Sisram的注射类业务持续在市场取得强劲表现。继2025年取得卓越业绩后，其旗舰产品Profhilo在整个2026年于泰国高端医美领域保持了强劲的发展势头。该产品受到顶级诊所和资深从业者的广泛采用，终端消费者需求持续旺盛，不仅巩固了Sisram在注射类产品领域的品牌地位，也促进了当地行业合作的拓展。

With both EBD and injectable lines gaining solid market traction, Sisram is capitalizing on cross-business synergies to develop tailored combination treatment protocols that cater to sophisticated local market needs. By combining Profhilo's skin remodelling and rejuvenation benefits with the advanced technology of Soprano Titanium, the Company has created customised regimens targeting high-demand aesthetic treatments in Thailand, including skin tightening, facial contouring and anti-ageing solutions..

随着能量源设备（EBD）和注射类产品线均获得强劲的市场增长势头，Sisram 正充分利用跨业务协同效应，开发量身定制的联合治疗方案，以满足当地市场日益精细化的需求。通过将 Profhilo 的皮肤重塑与焕活功效与 Soprano Titanium 的先进技术相结合，公司推出了针对泰国高需求医美治疗的定制化疗程，涵盖皮肤紧致、面部轮廓塑形及抗衰老解决方案。

This integrated approach enhances patient satisfaction and clinical outcomes. It enables partner clinics to deliver more comprehensive treatment packages and maximize the value of Sisram's full product range. The model also strengthens clinics' market competitiveness, boosts customer retention, and drives higher product penetration, broader channel coverage, as well as improved revenue and profitability — establishing a one-of-a-kind competitive edge in the local landscape..

这种综合方法提升了患者满意度和临床疗效。它使合作诊所能够提供更全面的治疗方案，并最大化复锐医疗科技全产品线的价值。该模式还增强了诊所的市场竞争力，提高客户留存率，推动更高的产品渗透率、更广泛的渠道覆盖，以及收入和盈利能力的提升——从而在当地市场中建立独一无二的竞争优势。

Mr. Eyal Ben David, CEO of Sisram Medical, commented: 'Thailand stands out as one of Southeast Asia's most vibrant medical aesthetics markets, underpinned by sound healthcare infrastructure, strong domestic demand and a booming medical tourism sector. Over the past year, we have ramped up local investment and expanded our presence, achieving healthy growth in both revenue and profit.'.

Sisram Medical 首席执行官 Eyal Ben David 先生表示：“泰国是东南亚最具活力的医美市场之一，这得益于其完善的医疗基础设施、强劲的国内需求以及蓬勃发展的医疗旅游行业。在过去一年中，我们加大了本地投资力度并扩大了市场布局，实现了营收和利润的健康增长。”

'Our progress in Thailand validates the strength of our global product portfolio, localized operating model and dual-growth strategy,' he continued. 'Going forward, we will further entrench Thailand as our key strategic base for the APAC region. We will expand our customer footprint, elevate medical education, technical support and after-sales services, and deepen synergies between our EBD and injectable businesses.

“我们在泰国取得的进展验证了我们全球产品组合、本地化运营模式以及双增长战略的强大实力，”他继续说道。“展望未来，我们将进一步巩固泰国作为我们在亚太地区的关键战略基地的地位。我们将扩大客户覆盖范围，提升医学教育、技术支持和售后服务水平，并深化我们EBD业务与注射类业务之间的协同效应。”

Through ongoing innovation and premium solution offerings, we are well positioned to serve local consumers and the fast-growing medical tourism market, and deliver sustainable, high-quality growth across the broader APAC market.'.

凭借持续的创新和优质的解决方案，我们处于有利地位，能够为本地消费者及快速增长的医疗旅游市场提供服务，并在更广泛的亚太地区市场实现可持续的高质量增长。

About Sisram Medical Ltd

关于复锐医疗有限公司

Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence, the Company's synergistic ecosystem spans EBD technologies, injectables, diagnostics, and complementary solutions.

复锐医疗科技有限公司（1696.HK）是全球医美解决方案的领导者，在能量源设备（EBD）领域拥有超过25年的专业经验。依托创新与临床卓越的深厚积淀，公司构建了协同发展的生态系统，业务涵盖能量源设备技术、注射类产品、诊断技术以及互补性解决方案。

Serving customers in over 110 countries and regions, Sisram delivers award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017..

Sisram 的业务遍及全球110多个国家和地区，为世界各地的数百万患者提供屡获殊荣的产品，在安全性、有效性及个性化医美护理方面树立新标杆。复星医药持有 Sisram 多数股权，自2017年9月起，Sisram 在香港联合交易所主板上市。

For more information, please visit:

如需更多信息，请访问：

www.sisram-medical.com

www.sisram-medical.com

.

。

SOURCE Sisram Medical Ltd

来源：复锐医疗有限公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示